IEQ Capital’s BridgeBio Pharma BBIO Stock Holding History

IEQ Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-66,520	Closed	-$5.09M	–	1906
2025 Q4	$5.09M	Sell	66,520 -6,500	-9%	-$427K	0.02%	518
2025 Q3	$3.79M	Buy	73,020 +49,697	+213%	+$2.42M	0.01%	555
2025 Q2	$1.01M	Sell	23,323 -3,606	-13%	-$131K	0.01%	858
2025 Q1	$931K	Buy	+26,929	New	+$908K	0.01%	776

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

IEQ Capital's BBIO Position: Q1 2026 in Review

IEQ Capital sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 66,520 shares — an estimated $5.09M sold.

IEQ Capital first reported a position in BBIO in Q1 2025 and held it in 4 quarters. The position peaked at $5.09M in Q4 2025. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

IEQ Capital reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
IEQ Capital sold 66,520 BridgeBio Pharma shares in Q1 2026, an estimated $5.09M.
IEQ Capital first reported a position in BridgeBio Pharma in Q1 2025 and held it in 4 quarters.
IEQ Capital's BridgeBio Pharma position peaked at $5.09M in Q4 2025.
460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on IEQ Capital's 13F filing for Q1 2026, filed 15 May 2026.